Metastatic colon cancer case study

Although these studies appear to have favorable outcomes for adding bevacizumab to combination chemotherapy, the exact utilization, schedule and timing of the administration of bevacizumab is still being investigated.

colon cancer case study pdf

Neurologic: Grossly normal. Preliminary results from the BEAT trial confirm similar results with a median progression-free survival of No severe adverse events were observed, except for mild fatigue and hand-foot syndrome.

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.

colorectal cancer case study examples

General appearance: Alert, pleasant, healthy-appearing gentleman who is in no acute distress. Inan estimatednew cases of colon cancer and 40, cases of rectal cancer resulted in 49, deaths.

Case study 91 colon cancer

Neurologic: Grossly normal. An irinotecan-based chemotherapy in combination with cetuximab Erbitux, Imclone. Although the majority of patients with metastatic colorectal cancer will die of their disease, the overall survival has increased from a few months to approximately 20 months in the last few years with the addition of chemotherapeutic agents such as irinotecan or oxaliplatin. No adjuvant chemotherapy was administered. In this patient with metastatic colon cancer that has progressed after treatment with FOLFOX plus bevacizumab, the most appropriate treatment recommendation would be which of the following: A. In , an estimated , new cases of colon cancer and 40, cases of rectal cancer resulted in 49, deaths. Single-agent irinotecan. This observational trial suggests that the continuation of bevacizumab after disease progression may result in better survival. The patient had metastatic para-aortic lymph nodes after the fifth tumor resection and underwent multiple lines of chemotherapy in April No severe adverse events were observed, except for mild fatigue and hand-foot syndrome. He was stable on this regimen for approximately 13 months. General appearance: Alert, pleasant, healthy-appearing gentleman who is in no acute distress.

Although the majority of patients with metastatic colorectal cancer will die of their disease, the overall survival has increased from a few months to approximately 20 months in the last few years with the addition of chemotherapeutic agents such as irinotecan or oxaliplatin.

The clinical effects of regorafenib monotherapy have shown a partial response according to Response Evaluation Criteria in Solid Tumors criteria.

Continuation of bevacizumab as a single agent.

Metastatic colon cancer case study

After that, liver metastasis, a duodenal metastasis with right renal invasion, right adrenal metastasis, and para-aortic lymph node metastases were observed during follow-up, and chemotherapy and resection were performed. Subsequently, at a median follow-up of 34 months, those patients treated with FOLFIRI and bevacizumab had a median survival of 28 months. At the time he was found to have progressive colon cancer, his energy level was slightly diminished. The addition of bevacizumab, a recombinant humanized version of a murine antihuman vascular endothelial growth factor monoclonal antibody known to play a key role in the regulation of angiogenesis and tumor growth, to irinotecan or oxaliplatin has also improved the outcomes for patients with metastatic colon cancer. Preliminary results from the BEAT trial confirm similar results with a median progression-free survival of Lymph nodes: There is no cervical, supraclavicular, infraclavicular, axillary or inguinal lymphadenopathy. In , an estimated , new cases of colon cancer and 40, cases of rectal cancer resulted in 49, deaths. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report. Severe adverse events associated with regorafenib are known to occur during the first and second courses of treatment. He had mild neuropathy.
Rated 8/10 based on 25 review
Download
Case Study: Treating Metastatic Colorectal Cancer